The Treatment With HBIG+GM-CSF+HBV Vaccine for Chronic Hepatitis B Patients With HBeAg Seroconversion
Status:
Unknown status
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
The host immunity has been generally recognized as the main factors to determine the outcome
of chronic hepatitis B virus (HBV) infection; however, previous studies have shown that
HBV-specific T cell and B cell function are exhausted in chronic hepatitis B (CHB) patients.
Recently, It is suggested that hepatitis B surface antigen (HBsAg) may play a key role in the
immune tolerance or immune exhaustion. Anti-HBV immune responses are partially recovered when
patients achieved hepatitis B e antigen (HBeAg) seroconversion during antiviral therapy, and
can be nearly recovered during HBsAg seroconversion. However, it is still difficult to
achieve the ideal terminal, HBsAg seroconversion. For this reason, immunotherapy would be
helpful to enhance the anti-HBV immunity and acquire higher HBsAg seroconversion. Here, the
investigators propose a hypothesis that hepatitis B immune globin
(HBIG)+granulocyte-macrophage colony-stimulating factor (GM-CSF)+HBV vaccine can enhance
anti-HBV immune responses and improve HBsAg seroconversion in CHB patients who has achieved
HBeAg seroconversion using nucleoside analogues treatment.